Perspective Therapeutics (CATX) CEO receives 735,000-option 2026 equity grant

Rhea-AI Filing Summary

Spoor Johan M. reported acquisition or exercise transactions in this Form 4 filing.

Perspective Therapeutics, Inc. reported that Chief Executive Officer Johan M. Spoor was granted stock options covering 735,000 shares on the March 2, 2026 grant date. The award, approved by the board on January 26, 2026, represents his annual 2026 equity grant. The options vest in 48 substantially equal monthly installments starting one month after the grant date, contingent on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spoor Johan M.

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.35	03/02/2026(1)		A		735,000		(2)	03/02/2036	Common Stock	735,000	$0	735,000	D

Explanation of Responses:

1. The option grant was approved by the Issuer's Board of Directors on January 26, 2026, with a grant date of March 2, 2026 (the "Grant Date"), and represents the Reporting Person's annual equity award for 2026.

2. Option vests and becomes exercisable over four years in 48 substantially equal monthly installments beginning on the date that is one month after the Grant Date, subject to the Reporting Person's continued service on each vesting date.

	/s/ Johan (Thijs) Spoor by Chris Nenno, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Perspective Therapeutics (CATX) CEO Johan Spoor receive in this Form 4?

Johan Spoor received a grant of stock options covering 735,000 shares as his 2026 annual equity award. The options were approved by the board and formally granted on March 2, 2026, according to the filing’s details and footnotes.

When was the Perspective Therapeutics (CATX) CEO stock option grant approved and granted?

The board approved the CEO’s option grant on January 26, 2026, with an official grant date of March 2, 2026. This timing is explicitly described as the “Grant Date” in the filing’s footnotes for the annual 2026 equity award.

How do Johan Spoor’s 735,000 Perspective Therapeutics (CATX) options vest?

The 735,000 stock options vest over four years in 48 substantially equal monthly installments. Vesting begins one month after the March 2, 2026 grant date and requires Johan Spoor’s continued service on each monthly vesting date to receive the shares.

What is the transaction code used in the Perspective Therapeutics (CATX) Form 4?

The transaction is reported with code “A,” indicating a grant, award, or other acquisition of derivative securities. The filing classifies it as a stock option grant rather than an open-market purchase or sale and shows no cash price paid for receiving the options.

Is Johan Spoor’s Perspective Therapeutics (CATX) option grant an open-market transaction?

No, the option grant is not an open-market trade. It is an equity award approved by the board as compensation, reported under transaction code “A,” with the options granted at no cash cost to Johan Spoor for the grant itself.

How many Perspective Therapeutics (CATX) derivative securities does Johan Spoor hold after this grant?

After the reported grant, Johan Spoor directly holds 735,000 stock options, according to the post-transaction balance in the Form 4. These options vest monthly over four years following the March 2, 2026 grant date, subject to his continued service.